Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages) Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentAcknowledgements
Afficher le documentScientific writers
Afficher le documentIntroduction
Afficher le documentTake-home messages
Ouvrir ce répertoire et afficher son contenuSection I - Setting the scene
Ouvrir ce répertoire et afficher son contenuSection II - Improving adherence rates: guidance for countries
Fermer ce répertoireSection III - Disease-Specific Reviews
Ouvrir ce répertoire et afficher son contenuChapter VII - Asthma
Ouvrir ce répertoire et afficher son contenuChapter VIII - Cancer (Palliative care)
Ouvrir ce répertoire et afficher son contenuChapter IX - Depression
Ouvrir ce répertoire et afficher son contenuChapter X - Diabetes
Ouvrir ce répertoire et afficher son contenuChapter XI - Epilepsy
Ouvrir ce répertoire et afficher son contenuChapter XII - Human immunodeficiency virus and acquired immunodeficiency syndrome
Ouvrir ce répertoire et afficher son contenuChapter XIII - Hypertension
Fermer ce répertoireChapter XIV - Tobacco smoking cessation
Afficher le document1. The burden of tobacco smoking
Afficher le document2. Clinical guidelines and therapies available for tobacco smoking cessation
Afficher le document3. Definitions
Afficher le document4. Epidemiology of adherence
Afficher le document5. Factors affecting adherence
Afficher le document6. Interventions for improving adherence
Afficher le document7. Cost, effectiveness and cost-effectiveness of adherence
Afficher le document8. Conclusions
Afficher le document9. References
Ouvrir ce répertoire et afficher son contenuChapter XV - Tuberculosis
Ouvrir ce répertoire et afficher son contenuAnnexes
Ouvrir ce répertoire et afficher son contenuWhere to find a copy of this book
 

8. Conclusions

Adherence to NRTs and to other treatments for tobacco dependence is very low in the long term (< 40%), but it shows a strong positive correlation with better cessation outcomes. Unfortunately, these long-term cessation outcomes are still unsatisfactorily low (< 20%).The data presented in this chapter are based mainly on clinical trials and three population-based studies. Therefore the data on adherence and cessation rates presented here might be over-optimistic.

In order to improve the accuracy and comparability of measured adherence rates, further research is needed to establish explicit definitions of "adherence to treatment" and treatment dropout. A clearer understanding and distinction between the different factors that influence dropout is also needed.

The patterns of both adherence to therapy and cessation rates over time suggest that interventions for improving adherence would be more cost-effective the earlier they are introduced into the programme (i.e. during the first 3 weeks).

Surprisingly, lack of access to cheap NRTs has been reported as an important reason for smokers in developed countries failing to quit. This is unexpected because the cost of NRTs is usually equivalent to the cost of smoking. Substituting the demand at the same price should not be a reason not to adhere.

There are few data available for identifying effective adherence-promoting interventions, but the use of antidepressant drugs and psychosocial behavioural supports has shown good results. Studies to evaluate the cost-effectiveness of interventions for improving adherence are required.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013